Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt

Cocaine-Related Disorders: early-phase trial registry

All 28 indexed Cocaine-Related Disorders trials have closed enrollment; the archived set skews early-phase.

Corpus placement: #577 of 28,707 conditions by registered trial count.

28 US clinical trials · none currently recruiting · #577 of 28,707 conditions by registered trial count

Cocaine-Related Disorders: 28 US clinical trials tracked, none currently recruiting.

Cocaine-Related Disorders is the subject of 28 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 4 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 17 of these trials.

Enrollment posture brief

Registry condition cocaine-related-disorders

OPEN 0 | RECR 0% | LATE 4 | EARLY 21 | RANK #577 | SPON 17

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Endometrial Carcinoma42.9%Anatomic Stage IB Breast Can25%Carcinoma, Hepatocellular25%Autistic Disorder17.9%Cocaine-Related Disorder (th…0%
Open-enrollment share among volume-matched conditions near Cocaine-Related Disorders

Cocaine-Related Disorders has no open enrollment in this registry pull (28 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cocaine-Related Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cocaine-Related Disorders is recruiting below its size-band peers.

    0 of 28 indexed trials (0%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cocaine-Related Disorders research.

    National Institute on Drug Abuse (NIDA) accounts for 17 of 28 trials (60.7%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Cocaine-Related Disorders trials plan to enrol fewer than 100 people.

    Median target enrolment is 41 among the 16 trials that report a genuine target (sentinel values excluded). 12 of those (75%) plan for fewer than 100 participants.

  4. Cocaine-Related Disorders research is mostly interventional.

    27 interventional and 1 observational studies make up this index (96.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 215Phase 31Phase 43

Indexed trials (enrollment closed)

28 total, page 1 of 1

COMPLETED Phase 2 208 participants

Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

University of Pennsylvania

NCT00142844

COMPLETED Phase 2 150 participants

Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals

New York State Psychiatric Institute

NCT00249483

COMPLETED Phase 1 140 participants

Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management

National Institute on Drug Abuse (NIDA)

NCT00292110

COMPLETED Phase 2 118 participants

Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention

The University of Texas Health Science Center, Houston

NCT02896712

COMPLETED NA 96 participants

Progesterone for the Treatment of Cocaine Dependence - 1

University of Minnesota

NCT00218257

COMPLETED Phase 2 60 participants

Ondansetron for the Treatment of Cocaine Dependence - 1

National Institute on Drug Abuse (NIDA)

NCT00033085

COMPLETED Phase 4 42 participants

Quetiapine for Cocaine Use and Cravings

Seattle Institute for Biomedical and Clinical Research

NCT00232336

COMPLETED Phase 2 41 participants

Gepirone vs Placebo in Treatment of Cocaine Dependence - 3

University of Pennsylvania

NCT00000189

COMPLETED NA 32 participants

Cocaine Abuse and Attention Deficit Disorder - 3

National Institute on Drug Abuse (NIDA)

NCT00000268

COMPLETED Phase 2 20 participants

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

New York State Psychiatric Institute

NCT00218543

COMPLETED Phase 1 17 participants

Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1

National Institute on Drug Abuse (NIDA)

NCT00136825

COMPLETED Phase 2 16 participants

Cocaine Abuse and ADHD - 10

National Institute on Drug Abuse (NIDA)

NCT00000275

COMPLETED 10 participants

Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

National Institute on Drug Abuse (NIDA)

NCT00000323

COMPLETED Phase 1 9 participants

Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid

Temple University

NCT03986762

COMPLETED Phase 1 8 participants

Cocaethylene as a Treatment for Cocaine Dependence - 1

National Institute on Drug Abuse (NIDA)

NCT00124696

COMPLETED Phase 1 8 participants

Cocaine-Methylphendidate Interaction Study - 4

National Institute on Drug Abuse (NIDA)

NCT00015067

COMPLETED Phase 4

Modeling Impaired Judgement in Cocaine Abusers - 6

National Institute on Drug Abuse (NIDA)

NCT00015236

COMPLETED Phase 3

Dose Response Trial of Pergolide for Cocaine Dependence - 1

Medical University of South Carolina

NCT00000248

COMPLETED Phase 2

Pharmacological Modulation of Cocaine Effects - 1

National Institute on Drug Abuse (NIDA)

NCT00000201

COMPLETED Phase 2

Risperidone Treatment in Dually-Diagnosed Individuals - 2

National Institute on Drug Abuse (NIDA)

NCT00000267

COMPLETED Phase 2

Evaluation of Benztropine for Cocaine Craving - 2

National Institute on Drug Abuse (NIDA)

NCT00000333

COMPLETED Phase 2

Disulfiram for Cocaine-Alcohol Abuse - 3

Yale University

NCT00000278

COMPLETED Phase 2

Effects of Labetalol on Human Cocaine Use - 8

National Institute on Drug Abuse (NIDA)

NCT00000291

COMPLETED Phase 4

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

National Institute on Drug Abuse (NIDA)

NCT00015301

COMPLETED Phase 2

Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1

National Institute on Drug Abuse (NIDA)

NCT00000266

COMPLETED Phase 2

IV Cocaine Abuse: A Laboratory Model - 1

New York State Psychiatric Institute

NCT00000212

COMPLETED Phase 2

Risperidone for the Treatment of Cocaine Dependence - 7

National Institute on Drug Abuse (NIDA)

NCT00000342

COMPLETED Phase 1

Prepulse Inhibition of Startle in Cocaine Dependence - 7

National Institute on Drug Abuse (NIDA)

NCT00015249

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 15
Phase 3 1
Phase 4 3

Named interventions

Most-linked intervention names on Cocaine-Related Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Flupenthixol Drug
2 trials
Disulfiram Drug
2 trials
Methylphenidate Drug
2 trials
Risperidone Drug
2 trials
Benztropine Drug
1 trials
Cocaethylene Drug
1 trials
Gepirone Drug
1 trials

US sites by state

Facility locations filed on Cocaine-Related Disorders trials. A trial with sites in several states counts in each.

New York 10 trials
Pennsylvania 3 trials
Maryland 3 trials
Texas 2 trials
South Carolina 2 trials
Minnesota 2 trials
Washington 1 trials
Virginia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cocaine-Related Disorders page

28 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cocaine-Related Disorders condition card totals 28 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.